European CHMP recommends paediatric license extension of glecaprevir / pibrentasvir (Maviret) for treatment of chronic hepatitis C infection

The proposed license extension is for the treatment of chronic hepatitis C virus (HCV) infection in children aged 3 years and older.

Source:

European Medicines Agency